中文简介

企业概述

江苏欧威医药有限公司成立于2012年8月6日，是江苏先声药业控股的创新药物研发企业，是江苏先声药业"百家汇"项目的第一家注册公司，注册资金500万元人民币。 2012年欧威公司申报南京"321"人才计划，获得200万元重点扶持。

主要产品

至2013年，公司现有在研创新项目3个，脑卒中药物项目已进入临床二期研究，另两个项目进入临床前研究阶段。欧威医药研发团队专业领域全面，主持或参与过先声药业多个一类新药的研发申报过程。

展望未来

欧威医药将依托先声药业的强大研发平台和资金投入，引进国外先进项目或推动内部项目走向国际，努力打造有世界影响力的药物。

英文简介

Founded on August 6th, 2012, Jiangsu Simovay Pharmaceutical Co., Ltd (Simovay) is a fully owned subsidiary of JiangSu Simcere Pharmaceutical Co., Ltd (Simcere). It’s also the first entity supported by “100 R & D Companies” project, with the registration capital of ￥5 million. In 2012, Simovay has applied Nanjing “321” talent projects, and was successfully awarded with ￥2 million research support. So far, Simovay has 3 innovative pipeline projects. Among them, an ischemic stroke project is undergoing phase II clinical trial, and the other two are at pre-clinical stage.

Simovay is a professional and energetic team, with broad and strong scientific backgrounds. The management team has led/participated in the development and filing process of more than one novel therapeutic drug in Simcere. With the support of established discovery platforms and capital investment from Simcere, Simovay will be devoted to in-licensing potential drug candidates from abroad, as well as advancing in-house drug development, so as to build Simovay a world-leading pharmaceutical company.